Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wen-Shen-Jian-Pi-Hua-Tan decoction (WSHT) is a traditional Chinese medicine (TCM) herbal formula that has been clinically used for the treatment of obesity and obesity-related metabolic diseases, particularly in patients with decreased or deficient function of the spleen and kidney according to TCM theory. Recent preclinical studies have demonstrated that WSHT can attenuate early renal lesions in animal models of obesity-related glomerulopathy by modulating renal bile acid composition, suppressing lipogenesis, reducing inflammation and fibrosis, and improving metabolic parameters such as dyslipidemia. Mechanistically, these effects are associated with upregulation of farnesoid X receptor (FXR), increased salt-induced kinase 1 expression, and inhibition of sterol regulatory element-binding protein-1c signaling pathways[1][2][6]. The formula is composed of multiple herbs; however, specific ingredient details are not provided in the cited sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wen-Shen-Jian-Pi-Hua-Tan decoction.